A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin

Start Date01 Feb 2026

Sponsor / Collaborator

Hanmi Pharmaceutical Co., Ltd.

NCT06174779

/ Active, not recruitingPhase 3

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus

Start Date03 Jan 2024

Sponsor / Collaborator

Hanmi Pharmaceutical Co., Ltd.

NCT03770728

/ TerminatedPhase 3

A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

Primary Objective:
To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone or in combination with sulfonylurea (SU).
Secondary Objectives:
* To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on glycemic control.
* To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on body weight.
* To evaluate the safety of once weekly injection of efpeglenatide.

Start Date01 Aug 2019

Sponsor / Collaborator

Sanofi

[+1]

100 Clinical Results associated with Efpeglenatide

100 Translational Medicine associated with Efpeglenatide

100 Patents (Medical) associated with Efpeglenatide

Literatures (Medical) associated with Efpeglenatide

01 Jan 2026·DIABETES OBESITY & METABOLISM

Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta‐analysis of randomized controlled trials

Review

Author: Rong Lin MD ; Kuo-Liong Chien PhD ; Ming-Chieh Shih PhD ; Chia-Li Hsu MD ; Hon-Yen Wu PhD

Abstract:

Aims:

To investigate the renal outcomes of dipeptidyl peptidase 4 (DPP‐4) inhibitors, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, and sodium‐glucose transport protein‐2 (SGLT‐2) inhibitors in patients with type 2 diabetes mellitus (T2DM) with chronic renal disease (CKD).

Materials and Methods:

PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched through July 2025 for randomized controlled trials with ≥24 weeks of follow‐up in patients with T2DM and CKD. Outcomes included composite renal outcome, estimated glomerular filtration rate (eGFR), and urinary albumin‐to‐creatinine ratio (UACR). A network meta‐analysis was conducted, and the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation used to evaluate evidence certainty (GRADE).

Results:

Twenty RCTs enrolling 80,670 participants were included. Compared with placebo, several agents significantly reduced composite renal outcomes, with dapagliflozin 10 mg showing the greatest efficacy (OR 0.55, 95% CI 0.42–0.72; high‐certainty evidence), followed by canagliflozin, empagliflozin, efpeglenatide, sotagliflozin 400 mg, semaglutide, and dulaglutide 1.5 mg. Canagliflozin 100–300 mg significantly reduced UACR, whereas dapagliflozin had no effect. None of the novel antidiabetic agents significantly altered eGFR. Certainty of evidence ranged from high for placebo‐controlled comparisons to low or very low for indirect estimates.

Conclusions:

In patients with T2DM and CKD, SGLT2 inhibitors provide the most consistent renal protection, while GLP‐1 receptor agonists offer additional but variable benefits. Dapagliflozin showed the greatest efficacy, and canagliflozin most strongly reduced albuminuria, highlighting meaningful heterogeneity across agents. DPP‐4 inhibitors conferred no renal benefit. Overall, evidence from placebo‐controlled trials was robust, whereas certainty was lower for indirect estimates, highlighting the need for drug‐specific evaluation in clinical practice.

05 Nov 2025·Cureus Journal of Medical Science

Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis

Review

Author: Rishu ; Balaji, Hariharasudhan ; Joy, Sandra ; Singh, Gaurav Pratap ; Li Cai, Chao Yuan ; Pongen, Bendangjungla ; Kolli, Mahesh ; Rai, Abigail ; Sai A K, Shahid

Type 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing the need for therapies that extend benefits beyond glycemic control. Injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated both cardioprotective and renoprotective potential, but the comparative efficacy of individual agents remains uncertain. This network meta-analysis (NMA) evaluated and ranked the effects of GLP-1 RAs on major adverse cardiovascular events (MACE) and renal composite outcomes, both prespecified as co-primary endpoints. A systematic search of PubMed, Scopus, ScienceDirect, Web of Science, and the Cochrane Library was conducted from inception to January 2024. Eligible randomized controlled trials enrolled adults with T2DM, including those with or without established cardiovascular disease or chronic kidney disease. Renal composite outcomes were defined as a decline in estimated glomerular filtration rate (eGFR) and/or onset of macroalbuminuria. Direct and indirect evidence were synthesized using a frequentist NMA framework to generate odds ratios (ORs) with 95% confidence intervals (CIs), while treatment hierarchy was assessed with Surface Under the Cumulative Ranking Curve (SUCRA) values. Transitivity and consistency assumptions were tested and satisfied, and the risk of bias was assessed with the Cochrane RoB2 tool. Fifteen randomized trials involving a pooled sample of more than 90,000 participants were included. Efpeglenatide ranked highest for both MACE (OR: 0.74; 95% CI: 0.62-0.87; SUCRA: 81.5%) and renal outcomes (OR: 0.68; 95% CI: 0.57-0.81; SUCRA: 81.33%), underscoring its clinical significance over other effective agents such as albiglutide and semaglutide. Albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant benefits, albeit with lower rankings. No major inconsistency or publication bias was detected. In conclusion, this NMA reinforces the class-wide cardiorenal benefits of GLP-1 receptor agonists while emphasizing variations in efficacy among individual agents, the limited evidence base for certain drugs, and the need for future head-to-head trials specifically designed to evaluate cardiovascular and renal endpoints.

01 Nov 2025·JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists

Review

Author: Federici, Massimo ; Angiolillo, Dominick J ; Bernardi, Marco ; Sciarretta, Sebastiano ; Simeone, Beatrice ; Benenati, Stefano ; Ortega-Paz, Luis ; Rocco, Erica ; Greco, Ernesto ; Spadafora, Luigi ; Mehran, Roxana ; Crea, Filippo ; Laudani, Claudio ; Sarto, Gianmarco ; Frati, Giacomo ; D'Amario, Domenico ; Galli, Mattia

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.

OBJECTIVES:

Previous meta-analyses of GLP-1 RAs have been limited by restricted populations, omission of recent trials, or incomplete safety synthesis; this study integrates the latest evidence across 21 randomized controlled trials and diverse populations using advanced meta-analytic methods.

METHODS:

Randomized controlled trials comparing GLP-1 RAs vs controls or placebo were included. Analyses were conducted in prespecified subgroups based on the GLP-1 RA used. Prespecified subgroups according to diabetes mellitus, kidney function, obesity, or heart failure were also performed. Main outcomes comprised mortality (all-cause and CV), trial-defined major adverse cardiovascular events (MACE) and serious adverse events. GRADE (Grading of Recommendations Assessment, Development and Evaluation) and trial sequential analyses were performed to evaluate certainty and conclusiveness of findings, respectively.

RESULTS:

A total of 21 trials encompassing 99,599 patients were included. Eight different GLP-1 RAs were used (lixisenatide, liraglutide, exenatide, semaglutide, efpeglenatide, dulaglutide, albiglutide, and tirzepatide), each administered at therapeutic doses and compared vs placebo or controls. Mean follow-up duration was 2.4 years. We found conclusive, high-certainty evidence that GLP-1 RAs reduced all-cause death (incidence rate ratio [IRR]: 0.88; 95% CI: 0.84-0.92; needed to treat [NNT] = 121), CV death (IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170), and MACE (IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66), compared with controls. GLP-1 RAs reduced serious adverse events (-9%), myocardial infarction (-15%), acute kidney failure (-9%), heart failure (-15%), and infections (-10%), but increased gastrointestinal (+63%) and gallbladder (+26%) disorders. There were no differences in stroke, pancreatitis, or neoplasm between groups. Results were mostly consistent across subgroups. Analysis by GLP-1 RA type revealed potential differences in efficacy and safety profiles.

CONCLUSIONS:

GLP-1 RAs reduce mortality and MACE in high-risk populations, highlighting benefits beyond glycemic control. These come at increased gastrointestinal and gallbladder risks. Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals. (PROSPERO [GLP-1 RAs Reduce Mortality and Cardiovascular Events Across the Spectrum of Treated Patients: A Systematic Review and Meta-Analysis]; CRD420251032222).

News (Medical) associated with Efpeglenatide

12 Feb 2026

·endpoints.news

Sanofi’s new CEO Belén Garijo gets frosty reception as Dupixent challenge awaits

The negative reaction to the impending departure of Sanofi CEO Paul Hudson, and Merck KGaA leader Belén Garijo as his replacement, is perhaps surprising given the French company’s muted performance under Hudson’s leadership. Sanofi’s shares fell about 3% in Paris and 4% in New York, a cold shoulder that may simply reflect the scale of the challenge that Garijo faces when she takes the reins in late April. She’ll have less than five years before the company’s immunological juggernaut Dupixent goes generic. Investors are concerned Garijo doesn’t have a track record of delivering R&D productivity at Merck KGaA, Jefferies managing director Michael Leuchten told Endpoints News in an interview. He considers that criticism “a little unfair” because the German conglomerate focused its capital allocation on areas other than pharma. “We thought the negative reaction on share price was harsh and kind of misses some of the nuances of what may be going on here,” Leuchten said. The company’s shares have lost about a quarter of their value in the past year. Garijo and her team will have to find pragmatic ways to extend Dupixent’s exclusivity, which could be possible through patent settlements and building on its joint venture with Regeneron, because there isn’t time to “rebuild an R&D organization from scratch” before Dupixent’s patent expires, Leuchten said. “One scenario that I think is possible is for Sanofi to go and acquire some assets that they fully fund and put those assets into the joint venture,” Leuchten said. Sanofi’s strategic priorities will remain unchanged under Garijo, a company spokesperson told Endpoints in an email. At Merck KGaA, Garijo’s history of dealmaking wasn’t scintillating. The biggest deal the company closed under her leadership was the $3.9 billion SpringWorks acquisition , and the rare cancer drugs Merck KGaA obtained haven’t been particularly lucrative so far. Another aspect driving some of the skepticism is that Garijo has had trouble delivering on promises in the past. In a letter in early 2022, she set out a goal for Merck KGaA known as “25 by 25” — achieving €25 billion ($27 billion) in total sales by 2025. The group won’t report its 2025 earnings until next month, but last October it guided to 2025 net sales between €20.8 billion and €21.4 billion. This missed goal is undeniably partly due to pipeline misfires. The failure of Merck KGaA’s evobrutinib in multiple sclerosis in late 2023 was followed by the cancellation of the pivotal trial of the head and neck cancer drug xevinapant in June 2024, after an interim analysis concluded the study was headed for failure. But Sanofi’s efforts to improve its drug development under Hudson didn’t always go as planned either. In 2019, at the beginning of his tenure as CEO, Hudson highlighted six programs as priorities. Two made it to market, Qfitlia (for hemophilia) and Beyfortus (for respiratory syncytial virus), but the others have either disappointed or failed entirely. Hudson also stopped developing a GLP-1 program for diabetes called efpeglenatide, just as other drugmakers were stepping up development efforts of this mechanism in obesity. There is no guarantee that asset would have gone on to do well, but the decision looks poor in retrospect. Sanofi’s current strategy involves going big on vaccines and investing in deals with a budget of up to €15 billion to spend across four key therapeutic areas: immunology, vaccines, neurology and rare diseases. This seems unlikely to compensate for Dupixent’s loss of exclusivity, since the drug accounted for 36% of Sanofi’s 2025 revenues. It was perhaps Sanofi’s eagerness on immunology that led things to go wrong at the French drugmaker under Hudson in the first place, Leuchten said. Sanofi assumed that immunology can be approached rationally and with acceptable risk, but time has shown that the space is “a lot more complicated than we thought,” Leuchten said. “The placebo response rates are all over the shop, you get intratrial variability, so the rational approach doesn’t work as well as anybody thought.” Sanofi’s change at the top seems to have happened fast; CEO transitions can be planned around a year in advance in the normal run of things. But Sanofi has ousted leaders with unceremonious haste before. In 2014 it sacked then-CEO Chris Viehbacher after a boardroom clash over Viehbacher’s management style.

Executive Change

28 Jan 2026

·www.prnewswire.com

Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment. Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on January 28 that it has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, its GLP-1 obesity therapy, as well as the Dapalon Family, Hanmi's flagship diabetes treatment portfolio (Dapalon Tab. and Dapalon Duo SR Tab.). Under the agreement, Hanmi will supply efpeglenatide and the Dapalon Family, while Laboratorios Sanfer will be responsible for regulatory approval, marketing, distribution, and sales within Mexico. Mexico is one of the countries with the highest obesity rates globally, with obesity prevalence reaching 36.86%, while diabetes prevalence stands at 16.4%.[1] As demand in the market extends beyond weight loss and maintenance therapy to include blood glucose management, the agreement reflects confidence in efpeglenatide's global scalability and strategic value. Founded in 1941, Sanfer is Mexico's largest privately held pharmaceutical company. Leveraging its extensive sales and distribution network across Latin America and its in-house R&D capabilities, Sanfer has established itself as a leading pharmaceutical company in the region. The company operates in more than 20 countries across Latin America as well as in the United States and recently strengthened its position as Mexico's largest biopharmaceutical company through the acquisition of Probiomed. The partnership is expected to gradually expand collaboration across efpeglenatide and other metabolic disease treatments, including additional product launches and joint marketing strategies over the mid- to long term. Ricardo Amtmann, CEO of Sanfer, stated, "As a leading pharmaceutical company in Mexico and Latin America, our vision is to improve patients' lives through innovative, high-quality products. With healthcare costs accounting for 34.6% of household spending in Mexico, improving accessibility to innovative treatments is critical.[2] Hanmi's efpeglenatide and diabetes treatment portfolio meet these needs." He added, "Through this partnership, we aim to contribute to addressing the rapidly growing challenges of obesity and diabetes in Mexico." Jae-hyun Park, CEO of Hanmi Pharmaceutical, said, "This agreement marks an important milestone that demonstrates Hanmi's formulation capabilities and R&D competitiveness on the global stage. As the Mexican government places greater emphasis on standardizing healthcare services and strengthening the management of chronic diseases, we find it especially meaningful that Hanmi's independently developed, Korea's first GLP-1–based obesity and metabolic disease treatment, together with our innovative diabetes treatment portfolio, will be able to contribute to improving the health of the Mexican population." Meanwhile, Hanmi completed its regulatory application for efpeglenatide to the Ministry of Food and Drug Safety on December 17, 2025. In September 2025, the company also submitted an IND for a Phase 3 clinical trial evaluating combination therapy with SGLT-2 inhibitors and metformin, which was approved on January 21, 2026. Hanmi is pursuing an expansion of efpeglenatide's indications from obesity into diabetes, with obesity approval targeted for the second half of 2026 and an additional diabetes indication planned for 2028. Contact info: Official Websites: , [email protected], +82-02-410-0467 SOURCE Hanmi Pharmaceutical 21% more press release views with Request a Demo

AcquisitionPhase 3

06 Nov 2024

·pipelinereview.com

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

Fat Loss Augmentation + Lean Mass Increase Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeek High Quality Obesity Management by Targeting the CRF2 Receptor: Enhanced Fat Loss with Lean Mass Increase Improved Weight Loss and Muscle Preservation with HM15275 Combination Therapy SEOUL, South Korea I November 6, 2024 I Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss but also significantly increases lean muscle mass, marking it as a potential game-changer in obesity management. HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. “HM17321 is the novel concept of obesity drug developed combining advanced artificial intelligence and structural modeling technology with Hanmi’s innovative R&D expertise,” said Dr. In Young Choi, Head of Hanmi’s R&D Center. “It selectively reduces fat while increasing muscle, establishing a new paradigm for high quality obesity treatment. The drug shows significant promise as both monotherapy and combination therapy to improve weight loss potency and quality,” he added. As a peptide-based therapy, HM17321 is anticipated to provide a more cost-effective alternative to antibody-based muscle-preserving drugs, such as myostatin-targeting monoclonal antibodies (mAbs), while also demonstrating enhanced compatibility with incretin-based obesity treatments. Hanmi unveiled its latest findings at 2024 ObesityWeek, an annual obesity-focused conference held in San Antonio, Texas, from November 3 to 6. Hanmi presented two preclinical studies in poster format, underscoring HM17321’s double-action(fat loss and lean muscle gain) benefits and a development strategy that highlights both quantitative and qualitative improvements in weight loss. Unlike conventional incretin-based drugs, HM17321 targets the CRF2 (Corticotropin-Releasing Factor 2) receptor to selectively reduce fat while enhancing muscle mass. This unique approach sets it apart from existing therapies. Current GLP-1-based obesity medications are effective in achieving 15-20% weight loss, but up to 40% of this loss can come from muscle, accompanied by a reduction in basal metabolic rate and a high risk of rapid weight regain (the “yo-yo” effect) after discontinuation. Hanmi reported at the conference that, in animal models, HM17321 achieved weight loss levels comparable to semaglutide, a prominent GLP-1-based therapy, but with the added benefit of increased lean body and muscle mass. This capability makes HM17321 a first-in-class drug, providing a differentiated strategy to high quality weight management by focusing on both fat loss and muscle enhancement simultaneously. In addition to HM17321, Hanmi presented a separate study on the combined use of HM17321 with HM15275, a next-generation anti-obesity drug (LA-GLP/GIP/GCG), and semaglutide. The combination therapy demonstrated a substantial reduction in body weight and fat mass compared to monotherapies, effectively preventing the muscle loss that accompanies significant weight loss treatments. These findings underscore HM17321’s role in improving the quality of weight loss by reducing fat, increasing muscle mass, and enhancing muscle function, making it advantageous in both monotherapy and combination therapies. Hanmi also presented follow-up nonclinical data on HM15275(LA-GLP-1/GIP/GCG), previously unveiled at the American Diabetes Association (ADA) conference. This novel anti-obesity candidate not only demonstrates potential for over 25% weight loss with minimal muscle loss but also offers therapeutic benefits for metabolic diseases. At 2024 ObesityWeek, Hanmi highlighted HM15275’s mechanism of action, which facilitates favorable metabolic phenotype change and enhances energy metabolism alongside dietary control. These effects clearly highlight how HM15275 could distinguish itself from current incretin-based obesity drugs, which primarily rely on appetite suppression. HM15275 is currently in Phase 1 clinical trials in the United States, with plans to progress to Phase 2 trials by 2025, positioning it as a ‘best-in-class’ candidate in obesity treatment. Reflecting on these innovative R&D achievements, Dr. Choi stated, “This year, Hanmi has fortified its leadership in obesity treatment through the unveiling of HM17321 and HM15275. These innovations continue the momentum started by efpeglenatide within our H.O.P project. Our commitment to pioneering R&D will drive unprecedented advancements in obesity treatment, addressing challenges once thought insurmountable.” Official Website: www.hanmipharm.com SOURCE: Hanmi Pharmaceutical

Phase 1Clinical Result

100 Deals associated with Efpeglenatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11947	-	-	DB15650

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 3	South Korea	Hanmi Pharmaceutical Co., Ltd.	03 Jan 2024
Diabetes Mellitus, Type 2	Phase 3	United States	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	United States	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Germany	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Germany	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Poland	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Poland	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Ukraine	Hanmi Pharmaceutical Co., Ltd.	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	Ukraine	Sanofi	05 Dec 2017
Diabetes Mellitus, Type 2	Phase 3	United Kingdom	Sanofi	05 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03496298 (AMPLITUDE-O, Pubmed \| Circulation)	Phase 3	Diabetes Mellitus, Type 2	4,076	Placebo	qyottsoqup(dhbaltntvn) = rhnhzmblvx htznoflvje (sgpltjixsw )	-	20 Feb 2023
				Efpeglenatide 4 mg	qyottsoqup(dhbaltntvn) = sjwnggrlqx htznoflvje (sgpltjixsw )
NCT03353350 (AMPLITUDE-M, Pubmed)	Phase 3	Diabetes Mellitus, Type 2	406	Efpeglenatide 2 mg	runihfvxyg(lfcptjrbma) = rvifintcvb mkbxxyrmme (jzyepaaezy )	Positive	07 Jun 2022
				Efpeglenatide 4 mg	runihfvxyg(lfcptjrbma) = uqmvkndrvi mkbxxyrmme (jzyepaaezy )
NCT03353350 (AMPLITUDE-M, CTgov)	Phase 3	Diabetes Mellitus, Type 2	406	placebo (Placebo)	iyfeehirnh(eizfrajllf) = sspijowdtn ydfnaygvah (uatymuheiv, 1.16) View more	-	18 Jan 2022
				efpeglenatide (SAR439977) (Efpeglenatide 4 mg)	iyfeehirnh(eizfrajllf) = kvpjvkvqqd ydfnaygvah (uatymuheiv, 1.01) View more
NCT03713684 (AMPLITUDE-L, CTgov)	Phase 3	Diabetes Mellitus, Type 2	370	Background therapy (Placebo)	twqlzzprch(zdmjyogean) = gpmgcnlhib dgaglwiphe (yskglowiht, 1.09) View more	-	02 Dec 2021
				Background therapy+Efpeglenatide SAR439977 (Efpeglenatide 2 mg)	twqlzzprch(zdmjyogean) = wiusruofsg dgaglwiphe (yskglowiht, 0.95) View more
NCT03770728 (AMPLITUDE-S, CTgov)	Phase 3	Diabetes Mellitus, Type 2	312	Placebo+Metformin (Placebo)	wcpnrifxau(syedyvuswj) = dzmbigrkxa lvphewtwld (gfnrqasjvk, 0.92) View more	-	02 Dec 2021
				Metformin+Efpeglenatide SAR439977 (Efpeglenatide 2 mg)	wcpnrifxau(syedyvuswj) = loseamrxqy lvphewtwld (gfnrqasjvk, 0.88) View more
NCT03684642 (AMPLITUDE-D, CTgov)	Phase 3	Diabetes Mellitus, Type 2	908	Metformin+Efpeglenatide (Efpeglenatide 4 mg)	oqelumdywm(mzeyfxllxp) = roqbfvghak hzirxhsfzl (uapxrjpuut, 0.06) View more	-	01 Nov 2021
				Metformin+Efpeglenatide (Efpeglenatide 6 mg)	oqelumdywm(mzeyfxllxp) = xlpkaytjps hzirxhsfzl (uapxrjpuut, 0.06) View more
NCT03496298 (AMPLITUDE-O, CTgov)	Phase 3	Diabetes Mellitus, Type 2	4,076	Placebo (Placebo)	vfzhuhjcfo = womadmamvx wkraxmnaoy (afujxruovx, irwlfrbtve - qlfyrplunv) View more	-	15 Oct 2021
				Efpeglenatide (SAR439977) (Efpeglenatide 4 mg)	ugppwrmvuj(bnqfqavggi) = lqbsyssypw kiwzfevxyk (ppocpifmyc, tbhpocncte - kmgitigbta) View more
NCT03496298 (AMPLITUDE-O, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Diabetes Mellitus, Type 2	4,076	efpeglenatide	bdvmhiqvos(ipmkhgjapr) = wcyokzqvmv owgndrmcgk (vbimfmimme ) View more	Positive	02 Sep 2021
				Placebo	bdvmhiqvos(ipmkhgjapr) = nfstyxlmqc owgndrmcgk (vbimfmimme ) View more
NCT02075281 (BALANCE 205, EASD2019)	Phase 2	Prediabetic State \| Obesity	295	Efpeglenatide 4 mg QW	eicfktyloj(laoxbbtkar) = inhllgdfvm iogckfefar (kzjqszvegb )	Positive	17 Sep 2019
				Efpeglenatide 6 mg QW	eicfktyloj(laoxbbtkar) = tgvcaahjzo iogckfefar (kzjqszvegb )
NCT02081118 (EASD2015)	Phase 2	Diabetes Mellitus, Type 2	209	HM11260C 8mg	ijrsugtfok(wfxcbdcubp) = nidrkmzsns vswqyhvqvj (myreenkvly ) View more	Positive	16 Sep 2015
				HM11260C 12mg	ijrsugtfok(wfxcbdcubp) = wtuedlwsen vswqyhvqvj (myreenkvly ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis